AI assistant
ALNYLAM PHARMACEUTICALS, INC. — Director's Dealing 2025
Jul 2, 2025
29981_dirs_2025-07-02_888cd426-5671-4617-ba74-eac4c9cd10ec.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK: 0001178670
Period of Report: 2025-07-01
Reporting Person: Fitzgerald Kevin Joseph (CSO & EVP, Head of Research)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-07-01 | Common Stock | A | 7763 | $0.0 | Acquired | 21264 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 537 | Indirect |
Footnotes
F1: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
F2: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.